查看购物车
  • Traditional Chinese
  • English
封面
市场调查报告书
商品编码
1871296

多癌种早期检测（MCED）测试市场机会、成长驱动因素、产业趋势分析及2025-2034年预测

Multi Cancer Early Detection (MCED) Test Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025 - 2034
出版日期: | 出版商: Global Market Insights Inc. | 英文 130 Pages | 商品交期: 2-3个工作天内

价格
简介目录

2024 年全球多癌症早期检测 (MCED) 测试市场价值为 15 亿美元，预计到 2034 年将以 14.1% 的复合年增长率增长至 58 亿美元。

多重癌种早期检测（MCED）测试市场 - IMG1

受全球癌症发病率上升、对早期诊断解决方案的需求不断增长以及分子诊断技术快速发展的推动，市场正呈现强劲成长动能。多组学早期诊断（MCED）检测利用液体活检和新一代定序（NGS）等方法，仅需一份血液样本即可检测多种癌症类型，从而重新定义了传统的筛检方法。这些检测使临床医生能够更早、更全面地识别癌症，并正在改变肿瘤学领域。这些公司透过不断改进液体活检技术、整合多组学资料以及人工智慧驱动的分析，提升检测的精确度和临床应用性，从而为多种癌症类型开发出高灵敏度和高特异性的诊断解决方案。

市场范围
起始年份 2024
预测年份 2025-2034
起始值 15亿美元
预测值 58亿美元
复合年增长率 14.1%

基因组检测、实验室自建检测 (LDT) 及其他相关细分市场预计到 2034 年将以 14% 的复合年增长率成长。此细分市场占据主导地位，原因在于其商业化进程较早、能够灵活地针对特定突变，以及医疗机构和研究机构的广泛采用。这些检测方法分析基因突变、甲基化模式和其他分子特征，从而支持多种癌症的个人化筛检。

预计到2034年，医院领域的市场规模将达到29亿美元。医院在管理复杂的诊断流程和多学科诊疗方面具有优势，肿瘤科医生、病理学家和遗传学家等专家通力合作，共同解读检测结果。这种团队协作能够确保早期精准检测，并为治疗方案的製定提供切实可行的指导。预防性医疗保健措施也进一步巩固了该领域的重要性。

北美多癌种早期检测 (MCED) 市场受益于人们对预防性医疗保健的高度重视、对精准肿瘤学的大力投入以及液体活检和基因panel筛检的早期应用。该地区先进的医疗保健基础设施和对早期诊断的重视，持续推动医院、实验室和健康管理项目对相关产品的需求。

多重癌种早期检测 (MCED) 市场的主要企业包括安派生物医学科技、燃石生物、EarlyDiagnostics、Elypta、Freenome Holdings、EXACT SCIENCES CORPORATION、Genecast Biotechnology、广州安科德医疗、GUARDANT HEALTH、Harbinger Health、GRAIL、Micron、SWelics 和 Sraemics。市场领导者透过投资先进的诊断技术（包括人工智慧驱动的分析和多组学整合）来增强自身实力，从而提高检测的准确性。他们积极拓展临床合作，加强与研究机构的合作，并专注于获得监管部门的批准，以提高检测的可近性。液体活检和基因panel检测的持续创新，以及早期商业化策略，使企业能够开拓新市场。此外，他们还优先考虑向医护人员和患者普及MCED检测的益处，投资于预防性医疗保健活动，并优化分销管道，以确保在医院、实验室和健康管理项目中广泛应用。

目录

第一章：方法论与范围

第二章：执行概要

第三章：行业洞察

  • 产业生态系分析
    • 供应商格局
    • 影响价值链的因素
  • 产业影响因素
    • 成长驱动因素
      • 癌症发生率不断上升
      • 癌症检出率高，加上对有效癌症检测工具的需求不断增长，使得人们更需要这些工具。
      • 资料分析和人工智慧 (AI) 在癌症筛检中的应用
    • 产业陷阱与挑战
      • 多种癌症筛检测试费用高昂
    • 市场机会
      • 拓展至预防保健及人口健康项目
  • 成长潜力分析
  • 监管环境
  • 技术格局
    • 当前技术趋势
    • 新兴技术
  • 未来市场趋势
  • 2024年定价分析
  • 专利分析
  • 报销方案
  • 波特的分析
  • PESTEL 分析

第四章：竞争格局

  • 介绍
  • 公司市占率分析
    • 全球的
    • 北美洲
    • 欧洲
  • 公司矩阵分析
  • 主要市场参与者的竞争分析
  • 竞争定位矩阵
  • 关键进展
    • 併购
    • 伙伴关係与合作
    • 新产品发布
    • 扩张计划

第五章：市场估算与预测：依类型划分，2021-2034年

  • 主要趋势
  • 基因检测、LDT 等
  • 液体活检

第六章：市场估算与预测：依最终用途划分，2021-2034年

  • 主要趋势
  • 医院
  • 诊断实验室
  • 其他最终用途

第七章：市场估计与预测：依地区划分，2021-2034年

  • 主要趋势
  • 北美洲
    • 我们
    • 加拿大
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 西班牙
    • 义大利
    • 荷兰
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳洲
    • 韩国
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿联酋

第八章：公司简介

  • AnPac Bio-Medical Science
  • Burning Rock Biotech
  • EarlyDiagnostics
  • Elypta
  • EXACT SCIENCES CORPORATION
  • Freenome Holdings
  • Genecast Biotechnology
  • Guangzhou AnchorDx Medical
  • GUARDANT HEALTH
  • Harbinger Health
  • GRAIL
  • Micronoma
  • SeekIn
  • Singlera Genomics
简介目录
Product Code: 11171

The Global Multi Cancer Early Detection (MCED) Test Market was valued at USD 1.5 billion in 2024 and is estimated to grow at a CAGR of 14.1% to reach USD 5.8 billion by 2034.

Multi Cancer Early Detection (MCED) Test Market - IMG1

The market is witnessing strong momentum, fueled by the rising prevalence of cancer worldwide, increasing demand for early diagnostic solutions, and rapid progress in molecular diagnostic technologies. MCED tests, leveraging methods such as liquid biopsy and next-generation sequencing (NGS), enable the detection of multiple cancer types from a single blood sample, redefining traditional screening approaches. These tests are transforming oncology by allowing clinicians to identify cancers earlier and more comprehensively. These companies enhance test precision and clinical applicability through continuous advancements in liquid biopsy techniques, integration of multi-omics data, and AI-driven analytics, creating highly sensitive and specific diagnostic solutions for a wide spectrum of cancer types.

Market Scope
Start Year2024
Forecast Year2025-2034
Start Value$1.5 Billion
Forecast Value$5.8 Billion
CAGR14.1%

The gene panel, laboratory-developed test (LDT), and other related segments are projected to grow at a CAGR of 14% through 2034. This segment dominates the market due to early commercialization, flexibility in targeting specific mutations, and adoption by healthcare providers and research institutions. These tests analyze genetic mutations, methylation patterns, and other molecular signatures, supporting personalized screening approaches across multiple cancers.

The hospitals segment is projected to reach USD 2.9 billion by 2034. Hospitals are preferred for managing complex diagnostic workflows and multidisciplinary care, with oncologists, pathologists, and geneticists collaborating to interpret test results. This teamwork ensures accurate early detection and actionable insights for treatment planning. Preventive healthcare initiatives further reinforce the segment's prominence.

North America Multi Cancer Early Detection (MCED) Test Market is supported by high awareness of preventive healthcare, robust investment in precision oncology, and early adoption of liquid biopsy and gene panel-based screening. The region's advanced healthcare infrastructure and focus on early diagnosis sustain demand across hospitals, laboratories, and wellness programs.

Key companies in the Multi Cancer Early Detection (MCED) Test Market include AnPac Bio-Medical Science, Burning Rock Biotech, EarlyDiagnostics, Elypta, Freenome Holdings, EXACT SCIENCES CORPORATION, Genecast Biotechnology, Guangzhou AnchorDx Medical, GUARDANT HEALTH, Harbinger Health, GRAIL, Micronoma, SeekIn, and Singlera Genomics. Market leaders strengthen their presence by investing in advanced diagnostic technologies, including AI-driven analysis and multi-omics integration, to improve test accuracy. They actively expand clinical collaborations, enhance partnerships with research institutions, and focus on regulatory approvals to increase accessibility. Continuous innovation in liquid biopsy and gene panel testing, alongside early commercialization strategies, allows companies to capture new markets. Additionally, they prioritize educating healthcare providers and patients about the benefits of MCED testing, invest in preventive healthcare campaigns, and optimize distribution channels to ensure wide availability across hospitals, laboratories, and wellness programs.

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market scope and definition
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Data mining sources
    • 1.3.1 Global
    • 1.3.2 Regional/country
  • 1.4 Base estimates and calculations
    • 1.4.1 Base year calculation
    • 1.4.2 Key trends for market estimation
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
  • 1.6 Forecast model
  • 1.7 Research assumptions and limitations

Chapter 2 Executive Summary

  • 2.1 Industry 360° synopsis
  • 2.2 Key market trends
    • 2.2.1 Regional trends
    • 2.2.2 Type trends
    • 2.2.3 End Use trends
  • 2.3 CXO perspectives: Strategic imperatives
    • 2.3.1 Key decision points for industry executives
    • 2.3.2 Critical success factors for market players
  • 2.4 Future outlook and strategic recommendations

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
    • 3.1.1 Supplier landscape
    • 3.1.2 Factors affecting the value chain
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Increasing prevalence of cancer
      • 3.2.1.2 High cancer detection rate coupled with growing demand for effective cancer tools
      • 3.2.1.3 Advancements in data analytics and artificial intelligence (AI) utilized in cancer screening
    • 3.2.2 Industry pitfalls and challenges
      • 3.2.2.1 High cost of multi-cancer screening tests
    • 3.2.3 Market opportunities
      • 3.2.3.1 Expansion into preventive care and population health programs
  • 3.3 Growth potential analysis
  • 3.4 Regulatory landscape
    • 3.4.1 North America
    • 3.4.2 Europe
    • 3.4.3 Asia Pacific
    • 3.4.4 Latin America
    • 3.4.5 Middle East and Africa
  • 3.5 Technology landscape
    • 3.5.1 Current technological trends
    • 3.5.2 Emerging technologies
  • 3.6 Future market trends
  • 3.7 Pricing analysis, 2024
  • 3.8 Patent analysis
  • 3.9 Reimbursement scenario
  • 3.10 Porter's analysis
  • 3.11 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

  • 4.1 Introduction
  • 4.2 Company market share analysis
    • 4.2.1 Global
    • 4.2.2 North America
    • 4.2.3 Europe
  • 4.3 Company matrix analysis
  • 4.4 Competitive analysis of major market players
  • 4.5 Competitive positioning matrix
  • 4.6 Key developments
    • 4.6.1 Merger and acquisition
    • 4.6.2 Partnership and collaboration
    • 4.6.3 New product launches
    • 4.6.4 Expansion plans

Chapter 5 Market Estimates and Forecast, By Type, 2021 - 2034 ($ Mn)

  • 5.1 Key trends
  • 5.2 Gene panel, LDT and others
  • 5.3 Liquid biopsy

Chapter 6 Market Estimates and Forecast, By End Use, 2021 - 2034 ($ Mn)

  • 6.1 Key trends
  • 6.2 Hospitals
  • 6.3 Diagnostic laboratories
  • 6.4 Other End use

Chapter 7 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)

  • 7.1 Key trends
  • 7.2 North America
    • 7.2.1 U.S.
    • 7.2.2 Canada
  • 7.3 Europe
    • 7.3.1 Germany
    • 7.3.2 UK
    • 7.3.3 France
    • 7.3.4 Spain
    • 7.3.5 Italy
    • 7.3.6 Netherlands
  • 7.4 Asia Pacific
    • 7.4.1 China
    • 7.4.2 India
    • 7.4.3 Japan
    • 7.4.4 Australia
    • 7.4.5 South Korea
  • 7.5 Latin America
    • 7.5.1 Brazil
    • 7.5.2 Mexico
    • 7.5.3 Argentina
  • 7.6 Middle East and Africa
    • 7.6.1 South Africa
    • 7.6.2 Saudi Arabia
    • 7.6.3 UAE

Chapter 8 Company Profiles

  • 8.1 AnPac Bio-Medical Science
  • 8.2 Burning Rock Biotech
  • 8.3 EarlyDiagnostics
  • 8.4 Elypta
  • 8.5 EXACT SCIENCES CORPORATION
  • 8.6 Freenome Holdings
  • 8.7 Genecast Biotechnology
  • 8.8 Guangzhou AnchorDx Medical
  • 8.9 GUARDANT HEALTH
  • 8.10 Harbinger Health
  • 8.11 GRAIL
  • 8.12 Micronoma
  • 8.13 SeekIn
  • 8.14 Singlera Genomics